Trade NAGE anytime, even after market hours
Regulated by
MAS
Trusted by
400,000+ users
Niagen Bioscience, Inc. (NAGE) is trading at US$3.25, up 1.09% today as of Aug 28, 11:53 EDT. The company has a market capitalisation of US$253.99M. Over the past 52 weeks, NAGE has traded between US$2.87 and US$10.52. On Syfe you can trade NAGE with $0 commission and add it to your watchlist.
| Previous close | US$3.21 |
|---|---|
| Market cap | US$253.99M |
| P/E ratio | 21.22 |
| 52-week range | US$2.87 – US$10.52 |
| Volume | 466.36K |
| Exchange | US |
Add to Watchlist
Set Price Alert
Niagen Bioscience, Inc.
Niagen Bioscience, Inc. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, Analytical Reference Standards and Services, and Pharmaceuticals. The Consumer Products segment provides finished dietary supplement products that contain the firm’s proprietary ingredients directly to consumers as well as to distributors. The Ingredients segment supplies ingredients as raw materials to the manufacturers of consumer products. The Analytical Reference Standards and Services segment includes supply of phytochemical reference standards and other research and development services. The Pharmaceuticals segment focuses on the pharmaceutical development of NAD precursor portfolio for potential therapeutic applications in rare diseases. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in 1999 and is headquartered in Los Angeles, CA.
Year: 2008
Sector Update: Healthcare Stocks Higher Monday Afternoon
Jul 13, 5:48 PM · MT Newswires
Sector Update: Healthcare
Jul 13, 5:23 PM · MT Newswires
Niagen Bioscience's NB4168 Gets US FDA Rare Pediatric Disease Tag for Ataxia Telangiectasia
Jul 13, 1:04 PM · MT Newswires
Niagen Bioscience Launches Program to Develop Therapies for Accelerated Aging and Rare Genetic Diseases
Jul 8, 1:17 PM · MT Newswires
Niagen Bioscience, Inc. (NAGE) stock is trading at US$3.25, +1.09% from the previous close of US$3.21.
The market cap for Niagen Bioscience, Inc. (NAGE) stock is approximately US$253.99M.
The price-to-earnings ratio for Niagen Bioscience, Inc. (NAGE) is 21.22, based on the latest reported earnings.
The 52-week high for Niagen Bioscience, Inc. (NAGE) stock is US$10.52.
The 52-week low for Niagen Bioscience, Inc. (NAGE) stock is US$2.87.
Niagen Bioscience, Inc. (NAGE) does not currently pay a dividend.
Stay on top of NAGE
Price moves, news and earnings — straight to your inbox.
Est. order value
US$0.00
Snapshot
